1 The Marlene and Paolo Fresco Institute for Parkinson's & Movement Disorders, Department of Neurology, Department of Neuroscience and Physiology, Neuroscience Institute, The Parekh Center for Interdisciplinary Neurology, NYU Grossman School of Medicine, New York, NY, USA.
2 Laboratory of Persistent Viral Diseases, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT, USA.
3 R&D Unit, Amprion Inc., San Diego, CA, USA. luis@amprionme.com.
4 AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany.
5 R&D Unit, Amprion Inc., San Diego, CA, USA.
6 Department of Biostatistics, College of Public Health, University of Iowa, Iowa City, IA, USA.
7 Michael J. Fox Foundation for Parkinson's Research, New York, NY, USA.
8 Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
9 AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany. roland.heym@abbvie.com.
10 R&D Unit, Amprion Inc., San Diego, CA, USA. claudio.soto@uth.tmc.edu.
11 Mitchell Center for Alzheimer's Disease and Related Brain Disorders, Department of Neurology, University of Texas Houston Medical School, Houston, TX, USA. claudio.soto@uth.tmc.edu.
12 Laboratory of Persistent Viral Diseases, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT, USA. bcaughey@nih.gov.
13 The Marlene and Paolo Fresco Institute for Parkinson's & Movement Disorders, Department of Neurology, Department of Neuroscience and Physiology, Neuroscience Institute, The Parekh Center for Interdisciplinary Neurology, NYU Grossman School of Medicine, New York, NY, USA. un.kang@nyulangone.org.